Pre-intervention SNOT-22 scores predict outcomes in aspirin exacerbated respiratory disease
Researchers have found in a new research that Preoperative SNOT-22 scores may be used as a predictor of postoperative, post-AD patient-reported outcomes in patient with aspirin exacerbated respiratory disease (AERD).The results of the study have been published in the American Journal of Otolaryngology.Edward C.Kuan and colleagues from the Department of Otolaryngology–Head and Neck...
Researchers have found in a new research that Preoperative SNOT-22 scores may be used as a predictor of postoperative, post-AD patient-reported outcomes in patient with aspirin exacerbated respiratory disease (AERD).
The results of the study have been published in the American Journal of Otolaryngology.
Edward C.Kuan and colleagues from the Department of Otolaryngology–Head and Neck Surgery, University of California, Irvine, CA, United States of America carried out this study to evaluate whether stratified preoperative, pre- aspirin desensitization (AD) sinonasal symptom scores predict postoperative, post-AD outcomes in Aspirin exacerbated respiratory disease (AERD).
The authors performed a retrospective chart review of a total of forty-seven patients, out of which 59.6% were female aged 48.0 ± 13.2 with aspirin challenge-proven AERD who underwent endoscopic sinus surgery followed by AD. Preoperative, postoperative/pre-AD, and postoperative/post-AD sinonasal symptom scores were collected (22-item Sino-Nasal Outcomes Test, SNOT-22).
Average time from surgery to AD was 70.0 ± 52.8 days. Preoperative SNOT-22 scores (n = 47) were divided into tertiles (cutoffs of 36 and 54 indicating mild [22.5 ± 13.7], moderate [44.3 ± 12.2], and severe [72.9 ± 19.7] disease). This corresponded to 12 (25.5%), 18 (38.3%), and 17 (36.2%) subjects being categorized into mild, moderate, and severe tertiles, respectively.
A longitudinal linear mixed-effects model was used for data analysis.
The investigation revealed the following results-
Postoperative, pre-AD SNOT-22 in all disease groups decreased and were not significantly different (12.3 ± 13.7, 11.1 ± 12.2, 22.7 ± 19.7; p = 0.074).
At short-term post-AD, only the severe group worsened (35.0 ± 20.3, p < 0.001), whereas other groups demonstrated negligible change (9.3 ± 14.3 and 14.4 ± 12.2).
At long-term post-AD, all groups redemonstrated convergence in symptom scores (23.7 ± 20.9, 19.4 ± 15.4, and 31.0 ± 27.6, p = 0.304).
Therefore, it was concluded that : Preoperative SNOT-22 scores may be used as a predictor of postoperative, post-AD patient-reported outcomes in AERD. Patients with mild and moderate disease may derive benefit from surgery and AD alone, while those with severe disease may require additional interventions (e.g., biologics)."
Next Story